Clinical Trials Browser

Phase 1/2 × famitinib × Thoracic × Clear all

NCT06332950 2024-03-27

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

Phase 1/2 Not yet recruiting

Small Cell Lung Carcinoma